Tirzepatide (Zepbound) produced more weight loss than semaglutide (Wegovy) in the head-to-head SURMOUNT-5 trial, with participants on tirzepatide losing on average 20.2 percent of body weight versus 13.7 percent on semaglutide at 72 weeks, the headline result on tirzepatide vs semaglutide. How to choose between these two medications depends on far more than that average scale result. The headline number is also the one most likely to lead you to the wrong decision.
We write this as clinicians, not as a comparison-shopping site. Our job is to match the molecule to the patient in front of us, using labs, side-effect history and cost structure together. What follows is how we actually make that call.
- Tirzepatide beat semaglutide head to head in SURMOUNT-5 (20.2 percent vs 13.7 percent average weight loss at 72 weeks).
- Side-effect profile, dosing flexibility, oral vs injectable preference and cost structure all matter alongside efficacy.
- A flat clinical fee with pharmacy-cost medication means the decision is made on clinical grounds, not on which choice makes the practice more money.
- Zepbound and Mounjaro are the same molecule (tirzepatide). cash-pay patients route to Zepbound and Mounjaro fits insurance-covered type 2 diabetes.
What the head-to-head data showed
SURMOUNT-5 enrolled adults with obesity and randomized them to tirzepatide 15 mg or semaglutide 2.4 mg, each titrated to the maximum tolerated dose over 72 weeks. Tirzepatide produced greater average weight loss at every measured time point. Approximately one in four tirzepatide participants lost 25 percent or more of their body weight, a result semaglutide did not reach at the same rate.
Trial averages describe populations, not you. Your labs, your GI sensitivity, your needle tolerance and your budget all change which of these two is actually the better drug for you.
The four factors that decide it
- Efficacy. Tirzepatide is the stronger agent on average. If maximum expected weight loss is the only variable that matters to you, the data favor tirzepatide.
- Side-effect tolerance. Both drugs cause nausea and GI symptoms and neither is universally easier. Patients who struggle on one sometimes tolerate the other well, which is why we trial, monitor and adjust rather than declare a winner in advance.
- Dosing and format. Tirzepatide is a once-weekly injection with a stepwise dose ladder. Semaglutide comes as a weekly injection and, as of 2026, an oral tablet (Wegovy Tablets) and there is also an oral GLP-1 (Foundayo, orforglipron) that removes injections entirely. If a pill beats a needle in your life, that changes the calculus.
- Cost structure. Here is where most platforms blur the truth, so we will not. Tirzepatide and semaglutide are priced by the pharmacy at cost, separately from your membership fee. There is no molecule upcharge and no dose-escalation fee on our side. If one drug is more expensive than the other at the pharmacy, you see that cost directly, with no margin added by us.
How the flat fee changes the conversation
Most telehealth platforms profit from the prescription itself. We do not. The Cardiometabolic Optimization Membership is a flat $299 per month, two-month commitment to start at $598, cancel anytime after. The fee covers the physician, the quarterly Biomarker Audit and the clinical protocols. The medication is billed directly by the pharmacy at cost.
A real objection, named plainly: 'If tirzepatide works better, why would a practice ever choose semaglutide for a patient?' Because a stronger drug is not a better drug for a patient who cannot tolerate it and because dose escalation on a platform that earns per-dose margin is a conflict of interest we deliberately designed out of our model. We make money when you get healthier, not when your dose gets stronger.
Which labs decide it
The quarterly Biomarker Audit guides the choice in both directions:
| Marker | Why it matters for the choice |
|---|---|
| HbA1c and fasting insulin | Higher values may favor the stronger agent (tirzepatide) when glycemic control is a priority |
| ApoB, Lp(a), lipids | Cardiovascular risk profile shapes whether a lipid-lowering medication is added alongside |
| Thyroid panel | Both drugs require normal thyroid function before titration |
| Hormone panel | Perimenopause and low testosterone change side-effect tolerance and weight-loss expectations |
We do not prescribe on a first visit without labs. If a platform is willing to hand you a GLP-1 without reading a single number, that tells you what they are selling.
What we tell patients who are torn
If you have no strong preference and no complicating history, we usually start with tirzepatide, because the head-to-head data are what they are. If you have GI sensitivity, needle aversion or a specific reason to prefer oral dosing, we start with the oral agent that fits and escalate only if the biomarkers say the result is not following. If you have type 2 diabetes with insurance, Mounjaro is often the right vehicle because it is the same molecule covered by your plan.
The right molecule is the one your labs, your side-effect history and your life actually support, not the one that wins a comparison chart.
Frequently asked questions
Is tirzepatide better than semaglutide for weight loss?
On average, yes. The SURMOUNT-5 head-to-head trial showed tirzepatide produced 20.2 percent average weight loss at 72 weeks versus 13.7 percent for semaglutide, with roughly one in four tirzepatide participants losing 25 percent or more of their body weight. Individual results vary and depend on dose tolerated, adherence and baseline metabolic health.
Is Zepbound the same as Mounjaro?
Yes. Both are tirzepatide. Zepbound is approved for chronic weight management and Mounjaro is approved for type 2 diabetes. Cash-pay patients are routed to Zepbound and patients with insurance covering diabetes treatment are often best served by Mounjaro through their plan. Same molecule, different approved use and different coverage path.
Is there an oral version of either drug?
Yes. Semaglutide is available as an oral tablet (Wegovy Tablets) and there is an oral GLP-1 (Foundayo, orforglipron) that requires no injections at all. Oral options trade some convenience for a daily rather than weekly schedule and can be the right choice for patients with needle aversion.
Which drug has fewer side effects?
Neither has a clean sweep. Both cause nausea, constipation and diarrhea in a meaningful share of patients and neither is universally better tolerated. Patients who struggle on one sometimes tolerate the other well. The way to know is to trial, monitor and adjust under clinical supervision rather than to pick from a chart.
Do I need labs before starting either medication?
Yes. Both require normal thyroid function and a metabolic panel before titration and the choice between them often changes once the full Biomarker Audit is read: ApoB, Lp(a), hs-CRP, HbA1c, fasting insulin and the hormone panel. Any platform willing to prescribe a GLP-1 without labs is selling a product, not practicing medicine.
How does pricing work for the medication?
The medication is billed directly by the pharmacy at cost, separately from the membership fee. There is no markup, no molecule upcharge and no dose-escalation fee on our side. If one drug costs more than the other at the pharmacy, you see that cost directly. The flat $299/month fee covers the doctor, the quarterly Biomarker Audit and the clinical protocols.
What if I start one and it does not work for me?
Switching between these two agents is common and straightforward under clinical supervision. Because the flat clinical fee does not change with the medication or the dose, a switch costs nothing on the membership side, only whatever the pharmacy charges for the new prescription at cost.
Related guides
- Cardiometabolic Optimization: the definitive guide
- How GLP-1s work and what happens when they stop
- Orforglipron: the oral GLP-1
- Our flat-fee model and why it never changes with your dose
External reference: the SURMOUNT-5 trial reports the head-to-head weight-loss data cited above.
References
- Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). 2022. pubmed.ncbi.nlm.nih.gov/35658024/
- Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). 2021. pubmed.ncbi.nlm.nih.gov/33567185/